derived_fields listlengths 1 1 | id stringclasses 10
values | price_increase_pct_trigger stringclasses 9
values | source stringclasses 2
values | source_quote stringclasses 10
values | state stringclasses 10
values | statute_citation stringclasses 10
values | url stringclasses 10
values | verified_fields listlengths 2 4 ⌀ | implementing_agency stringclasses 4
values | new_drug_wac_threshold stringclasses 5
values | reporting_deadline stringclasses 4
values | generic_biosimilar_trigger stringclasses 5
values | penalty_max stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
[
"state"
] | connecticut | 16% cumulative increase during the preceding two calendar years for drugs that cost $40 or more for a course of treatment | https://www.goodwinlaw.com/en/insights/publications/2025/06/alerts-lifesciences-state-drug-transparency-laws | HB 6669 updates the WAC increases that must be reported from a 20% WAC increase during the immediately preceding calendar year to a 16% cumulative increase during the preceding two calendar years for drugs that cost $40 or more for a course of treatment. | Connecticut | HB 6669 | https://referencesource.org/drug-price-transparency-thresholds/connecticut/ | [
"price_increase_pct_trigger",
"statute_citation"
] | null | null | null | null | null |
[
"state"
] | florida | 15% or more during the previous 12-month period or 30% or more cumulative during the preceding calendar years | https://www.goodwinlaw.com/en/insights/publications/2025/06/alerts-lifesciences-state-drug-transparency-laws | Fla. Stat. § 499.026 (2025), which requires drug manufacturers to report any WAC increase of 15% or more during the previous 12-month period or any cumulative WAC increase of 30% or more during the preceding calendar years. | Florida | Fla. Stat. § 499.026 | https://referencesource.org/drug-price-transparency-thresholds/florida/ | null | null | null | null | null | null |
[
"state"
] | louisiana | 50% for a 30-day supply | https://www.goodwinlaw.com/en/insights/publications/2025/06/alerts-lifesciences-state-drug-transparency-laws | LA. Stat. Ann. § 22:1657.1 requires drug manufacturers to notify the commissioner of insurance if one of their drugs with a WAC 1 of $100 or more has undergone a WAC increase of 50% or more for a 30-day supply. | Louisiana | LA. Stat. Ann. § 22:1657.1 | https://referencesource.org/drug-price-transparency-thresholds/louisiana/ | [
"implementing_agency",
"new_drug_wac_threshold"
] | commissioner of insurance | $100 | notification via email | null | null |
[
"state"
] | maine | insulin-specific: manufacturers must report WAC per pricing unit for each category of insulin | https://www.goodwinlaw.com/en/insights/publications/2025/06/alerts-lifesciences-state-drug-transparency-laws | S.P. 996 now requires manufacturers of insulin to notify the Maine Health Data Organization of the WAC per pricing unit for insulin produced by the manufacturer in each category of insulin. | Maine | S.P. 996 | https://referencesource.org/drug-price-transparency-thresholds/maine/ | [
"implementing_agency",
"statute_citation"
] | Maine Health Data Organization | null | null | null | null |
[
"state"
] | minnesota | null | https://www.goodwinlaw.com/en/insights/publications/2025/06/alerts-lifesciences-state-drug-transparency-laws | Minnesota: S.F. 2995 amends the state’s Prescription Drug Price Transparency Act to include some technical fixes and clarifications, such as explicitly including “biosimilars” along with generic drugs in the provision that triggers reporting when there is a WAC increase of at least 50% over the previous 12 months. | Minnesota | S.F. 2995 | https://referencesource.org/drug-price-transparency-thresholds/minnesota/ | [
"generic_biosimilar_trigger",
"statute_citation"
] | null | null | null | 50% over the previous 12 months | null |
[
"state"
] | new-jersey | more than 10% during any 12-month period | https://www.goodwinlaw.com/en/insights/publications/2025/06/alerts-lifesciences-state-drug-transparency-laws | NJ S.B. 1615 requires manufactures to report certain data points (e.g., NDC, sales volume, manufacturer costs, reasons for WAC increase) if it is increasing the WAC of a brand-name drug by more than 10% or increasing the WAC of a generic drug priced at $10 or more by more than 10% during any 12-month period. Additional... | New Jersey | NJ S.B. 1615 | https://referencesource.org/drug-price-transparency-thresholds/new-jersey/ | [
"generic_biosimilar_trigger",
"new_drug_wac_threshold",
"price_increase_pct_trigger",
"statute_citation"
] | null | $670 per WAC unit | null | generic drug priced at $10 or more by more than 10% during any 12-month period | null |
[
"state"
] | new-mexico | 10% in the previous calendar year or 16% over the previous two calendar years | https://www.goodwinlaw.com/en/insights/publications/2025/06/alerts-lifesciences-state-drug-transparency-laws | NM HB 33 requires drug manufacturers to report to the state data for any (1) drugs with a WAC of $400 or more for a 30-day supply, (2) course of treatment that is shorter than 30 days for a brand-name drug that has increased in WAC by 10% or more in the previous calendar year or by 16% or more over the course of the pr... | New Mexico | NM HB 33 | https://referencesource.org/drug-price-transparency-thresholds/new-mexico/ | [
"generic_biosimilar_trigger",
"statute_citation"
] | null | $400 for a 30-day supply | first reporting deadline June 1, 2025 | 30% or more over the previous calendar year | null |
[
"state"
] | new-york | more than 16%, including the proposed increase and the cumulative increases that occurred within the prior 24 months | https://www.goodwinlaw.com/en/insights/publications/2025/06/alerts-lifesciences-state-drug-transparency-laws | NY A1707 requires manufacturers to file a notice within 60 days of the planned effective date of an increase in price for prescription drugs with a WAC of more than $40 for a course of therapy if the increase in WAC is more than 16%, including the proposed increase and the cumulative increases that occurred within the ... | New York | NY A1707 | https://referencesource.org/drug-price-transparency-thresholds/new-york/ | [
"price_increase_pct_trigger",
"reporting_deadline",
"statute_citation"
] | null | null | within 60 days of the planned effective date of an increase in price | null | null |
[
"state"
] | oregon | 10 percent or more | https://dfr.oregon.gov/drugtransparency/pages/manufacturers.aspx | New drug reports due within 30 days of market entry Annual increase reports due March 15 (extended to April 15, 2026 for this year) 60-day price increase notices due 60 days before increase | Oregon | ORS 646A.680 through 646A.692 | https://referencesource.org/drug-price-transparency-thresholds/oregon/ | null | Division of Financial Regulation | $950 for a 30-day supply | New drug reports due within 30 days of market entry; Annual increase reports due March 15; 60-day price increase notices due 60 days before increase | 25 percent or more AND the increase is $300 or more | null |
[
"state"
] | texas | 15% or more in the previous year or 40% or more over the past three years | https://www.goodwinlaw.com/en/insights/publications/2025/06/alerts-lifesciences-state-drug-transparency-laws | 15% or more in the previous year or 40% or more over the past three years. If any FDA-approved drugs are sold in Texas, the manufacturer must also submit a report with the current WAC information to the Texas Health and Human Services Commission. Penalties for noncompliance may be up to $1,000 per day from the date on ... | Texas | Tex. Health & Safety Code § 441.0051-441.0054 | https://referencesource.org/drug-price-transparency-thresholds/texas/ | [
"implementing_agency",
"penalty_max",
"price_increase_pct_trigger"
] | Texas Health and Human Services Commission | $100 for a 30-day supply | null | same as brand | $1,000 per day |
State drug price transparency reporting thresholds, triggers, and penalties for pharmaceutical manufacturers
Canonical, always-current version: https://referencesource.org/drug-price-transparency-thresholds/ Machine-readable: https://referencesource.org/drug-price-transparency-thresholds/data.json — this mirror is a point-in-time copy.
- Last verified: 2026-10-06
- Stale after: 2027-02-10 (past this date, prefer the canonical copy — it re-verifies on a cadence this snapshot does not)
- Records: 10
State-by-state comparison of the dollar thresholds and percentage-increase triggers that require pharmaceutical manufacturers to report drug pricing information to state regulatory agencies. As of 2026, approximately 23 US states have enacted drug price transparency laws, each with different WAC (wholesale acquisition cost) thresholds for new drugs, different percentage-increase triggers for existing drugs, different reporting timeframes, and different penalty structures. Each record is one state with its reporting thresholds. Answers 'at what price or price increase must I report in [state]', 'what is the penalty for not reporting in [state]', and 'which states require drug price transparency reporting'.
Provenance — what every record carries
Every record carries source (the URL the value was read from) and
source_quote (a verbatim quote from that page stating it). A value you
cannot check against its page is indistinguishable from an invented one;
these can all be checked. Each record is also individually addressable on
the canonical site at its url.
Licence position
unknown
Facts are not copyrightable; what this dataset takes from each source is a fact plus a short attributed quote linking back to the page that states it.
Sources
- https://www.goodwinlaw.com/en/insights/publications/2025/06/alerts-lifesciences-state-drug-transparency-laws
- https://dfr.oregon.gov/drugtransparency/pages/manufacturers.aspx
Fields
See any record in data/records.jsonl — field names are self-describing,
and the canonical page for each record renders them with labels:
https://referencesource.org/drug-price-transparency-thresholds/
- Downloads last month
- 76